Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BEBT-209 plus systemic chemotherapy in advanced triple-negative breast cancer
CTR20223139Phase 2Completed
- Sponsor
- BeBetter Med
- Start
- Apr 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bebt-209, carboplatin, gemcitabine, paclitaxel and eribulin in triple-negative breast cancer (TNBC) (3 arms), sponsored by BeBetter Med. Primary endpoint: Progression-free survival. Started Apr 2023; status: completed.
02
Drugs
bebt-209carboplatingemcitabinepaclitaxeleribulin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20223139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223139.